Skip to main content
Innate Pharma logo

Innate Pharma — Investor Relations & Filings

Ticker · IPH ISIN · FR0010331421 LEI · 9695002Y8420ZB8HJE29 PA Manufacturing
Open in API
Filings indexed 1,403 across all filing types
Latest filing 2021-11-12 Foreign Filer Report
Country FR France
Listing PA IPH

About Innate Pharma

http://www.innate-pharma.com/

Innate Pharma is a clinical-stage, oncology-focused biotechnology company that develops immunotherapies for cancer patients. The company's scientific approach is centered on leveraging the innate immune system, particularly Natural Killer (NK) cells, to create novel treatments. Its innovative pipeline is composed of antibody-based therapeutics, including first-in-class monoclonal antibodies, antibody-drug conjugates (ADCs), and multi-specific NK cell engagers based on its proprietary ANKET® platform. Key clinical programs include lacutamab (anti-KIR3DL2), monalizumab (anti-NKG2A) in partnership with AstraZeneca, and a portfolio of NK cell engagers targeting various hematological malignancies and solid tumors.

Recent filings

Filing Released Lang Actions
INNATE PHARMA S.A. 6-K
Foreign Filer Report
2021-11-12 English
Informations privilégiées / Autres communiqués
Investor Presentation Classification · 1% confidence The document is a press release dated November 12, 2021, announcing that Innate Pharma is presenting preclinical data on a drug candidate (IPH6101 / SAR443579) developed with Sanofi at the annual congress of the Society for Immunotherapy of Cancer (SITC). This type of announcement, detailing scientific progress, partnership updates, and upcoming presentations at industry conferences, is characteristic of an Investor Presentation (IP) or a general corporate update. Since it is a formal announcement detailing scientific findings and strategic collaborations rather than a full financial report (10-K, IR) or a transcript (CT), the most fitting category is Investor Presentation (IP), as these releases often serve to inform investors about key scientific milestones. It is not an Earnings Release (ER) as it focuses on R&D data, not period financial results. It is not a Report Publication Announcement (RPA) because it is the primary source of the information (the data summary), not just a notice that a report is available.
2021-11-12 French
Inside Information / Other news releases
Earnings Release Classification · 1% confidence The document is dated November 12, 2021, and is structured as a press release announcing scientific data presentation at a conference (SITC Annual Meeting) and providing updates on a drug candidate (IPH6101/SAR443579) developed with a partner (Sanofi). It contains key highlights, scientific details, management quotes, and standard corporate boilerplate, including a disclaimer referencing the Annual Report on Form 20-F. This format is characteristic of an Earnings Release (ER) or a general corporate update, but since it focuses on scientific/pipeline progress rather than comprehensive financial results for a period, it aligns best with an announcement of significant corporate/research news. Given the options, it is a press release announcing key developments, which often overlaps with an Earnings Release if it coincides with reporting periods, but here it is clearly focused on R&D milestones. However, in the context of standard SEC filings, a press release announcing key operational/pipeline updates that are not explicitly financial results (like a 10-K or 10-Q) often falls under a general regulatory announcement or, if it contains key performance indicators, an Earnings Release. Since it highlights data supporting advancement into the clinic, it is a significant corporate announcement. Given the structure and content (highlights, quotes, scientific data), it most closely resembles an Earnings Release (ER) announcing operational/pipeline progress, or potentially a Regulatory Filing (RNS) if it were less structured. Since it provides 'highlights' and is a formal announcement, ER is the most appropriate fit among the specific options, as these often accompany or precede quarterly financial reporting, even if the focus is scientific. It is not a full report (10-K, IR), a presentation (IP), or a dividend notice (DIV). FY 2021
2021-11-12 English
INNATE PHARMA S.A. 6-K
Foreign Filer Report
2021-11-09 English
Inside Information / Other news releases
Call Transcript Classification · 1% confidence The document is titled "INNATE PHARMA ANNOUNCES CONFERENCE CALL AND WEBCAST FOR Q3 2021 BUSINESS UPDATE". It explicitly states that the company will hold a conference call to discuss business progress for the third quarter of 2021 and provides dial-in details and a webcast link for this event. This structure—announcing a future event where results or updates will be discussed, rather than containing the full results or the transcript itself—is characteristic of an announcement leading up to a call. Since the document is announcing a conference call, the most appropriate classification is Call Transcript (CT), assuming the user is interested in the event itself, or Report Publication Announcement (RPA) if it were announcing the release of a separate document. However, the primary focus is the announcement of the conference call event itself, which aligns best with the 'Call Transcript' category, as this announcement precedes the CT. Given the options, and the fact that it is announcing the mechanism for discussing results (a conference call), CT is the closest fit for the *event* being announced. If the document were the transcript, it would be classified as CT. Since it is the *announcement* of the call, it could also be RPA, but RPA is usually for announcing the publication of a formal report (like 10-K or IR). Because the core subject is the conference call, I will classify it as CT, recognizing it is the announcement *for* the CT event.
2021-11-09 English
Informations privilégiées / Autres communiqués
Report Publication Announcement Classification · 1% confidence The document is titled "INNATE PHARMA ORGANISE UNE CONFÉRENCE TÉLÉPHONIQUE ET UN WEBCAST POUR SES RÉSULTATS AU TROISIEME TRIMESTRE 2021" (Innate Pharma organizes a conference call and webcast for its third-quarter 2021 results). It explicitly announces the date, time, and dial-in details for a conference call intended to present the financial results and portfolio progress for the third quarter of 2021. This structure—announcing a call to discuss period results—is the defining characteristic of an Earnings Release (ER). Although it discusses Q3 results, the document itself is the *announcement* of the call, not the full transcript (CT) or the comprehensive quarterly report (IR). Therefore, it fits best as an Earnings Release (ER).
2021-11-09 French

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.